Embecta (FRA:JX7) ROCE % : 12.72% (As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Embecta ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Embecta's annualized ROCE % for the quarter that ended in Dec. 2024 was 12.72%.

Embecta ROCE % Historical Data

The historical data trend for Embecta's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Embecta ROCE % Chart

Embecta Annual Data

Trend

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

ROCE %

Get a 7-Day Free Trial

80.83

80.85

46.21

24.91

17.33

Embecta Quarterly Data
	Sep19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial														18.97	16.97	24.67	9.59	12.72

Embecta ROCE % Calculation

Embecta's annualized ROCE % for the fiscal year that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Sep. 2024 )		(A: Sep. 2023 )		(A: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Sep. 2024 )		(A: Sep. 2023 )		(A: Sep. 2024 )
	=	141.007	/	( ( (1137.893 - 331.23)	+	(1158.055 - 336.974) )	/ 2 )
	=	141.007	/	( (806.663	+	821.081)	/ 2 )
	=	141.007	/	813.872
	=	17.33 %

Embecta's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	103.904	/	( ( (1158.055 - 336.974)	+	(1097.773 - 284.781) )	/ 2 )
	=	103.904	/	( ( 821.081	+	812.992 )	/ 2 )
	=	103.904	/	817.0365
	=	12.72 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Embecta (FRA:JX7) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Embecta ROCE % Related Terms

Thank you for viewing the detailed overview of Embecta's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Embecta Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Embecta Corp (FRA:JX7) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

EMBC:USA

Address

300 Kimball Drive, Suite 300, Parsippany, NJ, USA, 07054

Website

https://www.embecta.com

Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.

Embecta Headlines

No Headlines